4 High Risk COVID Patients Administered With Antibody Cocktail Therapy

Four COVID-19 patients in Kolkata received Switzerland-based Roche's Antibody Cocktail, a drug with a combination of Casirivimab and Imdevimab. Administered to patients with mild to moderate COVID-19 infections, the drug has brought silver lining for patients with comorbidities. The drug stops the virus from entering the cells hence reducing the replication of the virus. No discomfort or other health issues related to the drug have been reported so far.